CD163 and psoriasis: In obese psoriasis patients, pioglitazone therapy did not significantly affect CD163+ (M2‐like) macrophage infiltration, indicating that its therapeutic impact is specifically targeted at CD68+ (M1‐like) pro‐inflammatory macrophages.